About Xencor

Xencor provides protein engineering technology platforms in the biotechnology industry. Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma; XmAb5574, a humanized monoclonal antibody that targets the antigen CD19 for the treatment of B cell malignancies; XmAb5592 for the treatment of myeloma; and XmAb5871 and XmAb7195, which are humanized monoclonal antibodies for the treatment of asthma and allergy. T

Company Highlights
Year Founded

1997

icon-altEmployees

275

Location (HQ)

USA

Since Last Funding

2 years 9 months

Monthly Website Visitors

4.8K

icon-altTotal Investment Amt

$500M

Last Funding Round

Post Ipo Equity

icon-altMoM Headcount Growth

-0.36%

icon-altYoY Headcount Growth

-5.5%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Biotechnology Research

Health Care

Therapeutics

Biotechnology